SandStar, a Charlotte, NC and Beijing, China-based AI+Retail tech company, received an investment from True Digital Group (TDG), a digital arm of True Corporation, a Thailand telecommunication company and an affiliate of the Thai conglomerate C.P. Group.
JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, acquired Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.
TikTok, the Chinese video-sharing social networking service, has launched a $200M creator fund.
Antengene Corporation, a Shangai, China-based hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, closed US$97m Series C financing round.
Xpeng Motors, a Guangzhou China-based smart electric vehicle company, raised its Series C+ financing of around US$500m.
Harbour BioMed, a Cambridge, MA, Rotterdam, NL, and Suzhou CN-based global, clinical stage biopharmaceutical company, completd its Series C financing of $102.8M.
DCM, a Menlo Park, Calif. – based early-stage global venture capital firm, closed its latest family of funds, totaling $880m.
CF PharmTech, Inc., a Suzhou, China-based maker of inhalation products, raised US $50M in Series F financing.
Zuoyebang, a Beijing, China-based online education technology company, raised $750M in funding.
Hutchison China MediTech Limited (Nasdaq/AIM: HCM) sold US$100m of shares at a price equivalent to US$25.00 per American Depositary Share via a private placement to General Atlantic, a global growth equity firm.
Geek+, a Beijing, China-based global provider of advanced robotics for logistics, closed its Series C funding round at over USD $200m in early 2020.
Immvira Group Company, a Shenzen, China-based biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, closed a $58m Series B financing.
VEsoft Inc., the Hangzhou, China-based developer of the Nebula Graph™ database, raised $8M in a series pre-A funding round.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, closed a $20m Series A financing of Zentera Therapeutics, a biopharmaceutical company with headquarters in Shanghai, China.
DataGrand, a Chinese AI startup that offers Natural Language Processing and RPA service to major enterprises in the nation, closed its CNY 270m (USD 38m) B+ funding round.